In an industry facing patent expirations and layoffs, vaccine products continue to offer good news, according to health care market research publisher Kalorama Information. The world market for preventative vaccines totaled $25.3 billion in 2010, up from $22.1 billion in 2009, according to its annual report on the industry, Vaccines 2011: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry. The report notes that the worldwide vaccine market is predicted to increase at a compound annual rate of 9.3% during the next five years, as new product introductions continue and the products are sold to emerging markets.
“Vaccines are a priority at the major companies and there has been no let-up in the business in the four years that we have been tracking it annually,” said Bruce Carlson, publisher of Kalorama Information. “We continue to see over nine percent growth in sales, and in some emerging markets the rate of growth is even faster. There is also a strong pipeline that should sustain growth as new products are launched.”
The health care market research firm indicated that sales to Latin America, India and China will grow at double-digit rates.
Vaccines are commonly segmented into two target markets, adult and pediatric. According to Kalorama Information, the pediatric vaccine market is larger, accounting for more than half of the total market. Pediatric vaccines are also growing at a faster rate than adult vaccines and this is expected to continue over the next five years. Pneumococcal and “combination” DTaP vaccines continue to drive growth in the pediatric sector, while influenza and hepatitis vaccine products are driving sales in the adult segment of the market.
The world vaccines market is dominated by five major competitors: Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Pfizer, and Novartis. Together, they held four-fifths of the market in 2010. All but Pfizer and Merck posted strong double-digit growth in their vaccine businesses. Sanofi Pasteur, a subsidiary of Sanofi Aventis, was the leading manufacturer, according to Kalorama Information, with GlaxoSmithKline a close second. The company’s position was largely due to its influenza products, although its polio/pertussis/Hib products also account for a significant portion of its vaccine sales.
Source: Kalorama Information
